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Predicting Outcome in dogs with Primary Immune-Mediated
Hemolytic Anemia: Results of a Multicenter Case Registry
R. Goggs, S.G. Dennis, A. Di Bella1, K.R. Humm1, G. McLauchlen1, C. Mooney1, A. Ridyard1,
S. Tappin1, D. Walker1, S. Warman1, N.T. Whitley1, D.C. Brodbelt1, and D.L. Chan1
Background: Outcome prediction in dogs with immune-mediated hemolytic anemia (IMHA) is challenging and few prog-
nostic indicators have been consistently identiﬁed.
Objectives: An online case registry was initiated to: prospectively survey canine IMHA presentation and management in
the British Isles; evaluate 2 previously reported illness severity scores, Canine Hemolytic Anemia Score (CHAOS) and Tokyo
and to identify independent prognostic markers.
Animals: Data from 276 dogs with primary IMHA across 10 referral centers were collected between 2008 and 2012.
Methods: Outcome prediction by previously reported illness-severity scores was tested using univariate logistic regression.
Independent predictors of death in hospital or by 30-days after admission were identiﬁed using multivariable logistic regres-
sion.
Results: Purebreds represented 89.1% dogs (n = 246). Immunosuppressive medications were administered to 88.4% dogs
(n = 244), 76.1% (n = 210) received antithrombotics and 74.3% (n = 205) received packed red blood cells. Seventy-four per
cent of dogs (n = 205) were discharged from hospital and 67.7% (n = 187) were alive 30-days after admission. Two dogs
were lost to follow-up at 30-days. In univariate analyses CHAOS was associated with death in hospital and death within 30-
days. Tokyo score was not associated with either outcome measure. A model containing SIRS-classiﬁcation, ASA classiﬁca-
tion, ALT, bilirubin, urea and creatinine predicting outcome at discharge was accurate in 82% of cases. ASA classiﬁcation,
bilirubin, urea and creatinine were independently associated with death in hospital or by 30-days.
Conclusions and clinical importance: Markers of kidney function, bilirubin concentration and ASA classiﬁcation are inde-
pendently associated with outcome in dogs with IMHA. Validation of this score in an unrelated population is now war-
ranted.
Key words: Canine hemolytic anemia objective score; Immune-mediated hemolytic anemia; Survival; Thromboembolism.
Immune-mediated hemolytic anemia (IMHA) isamong the most common autoimmune condition
aﬀecting dogs,1 and some aspects of its pathogenesis
have been well characterized.2,3 Despite such insights,
the prognosis for dogs with IMHA remains guarded,
with published case fatality rates for primary IMHA in
dogs ranging from 26% to 60%.4–6 Previous studies
have linked various clinicopathologic abnormalities with
outcome in dogs with IMHA. Few prognostic indica-
tors are consistent across multiple studies, however, per-
haps because of diﬀerences between study populations
or because of a lack of standardization. It has been sug-
gested that validation and standardization of diagnostic
criteria is urgently required for dogs with IMHA and
that future interventional clinical trials would beneﬁt
from stratiﬁcation by mortality risk.7 Mortality risk
assessment for clinical trials is typically performed using
illness severity scores.8 Accurate prognostication in a
complex disease process like IMHA might require a
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multifaceted scoring system. Two such schemes, the
canine hemolytic anemia objective score (CHAOS) and
a score developed in Japan (Tokyo) have been pro-
posed,a 9 but neither has been independently evaluated
to determine if they remain prognostic outside of the
populations from which they were generated.
Alternatives to these disease-speciﬁc illness severity
scores that might be easier to estimate are the American
Society of Anesthesiologists (ASA) health classiﬁcation
and the presence or absence of markers of a systemic
inﬂammatory response syndrome (SIRS). The ASA
classiﬁcation is typically used to evaluate patient risk
for anesthesia,10 but the classiﬁcation is easy to apply
and has been used as a marker of disease severity in
other canine populations.11 The inﬂammatory response
associated with IMHA in dogs is well-recognized and
can be evaluated through measurement of acute phase
proteins,12 or cytokine concentrations.13 These measures
are not widely available however, while a SIRS score
based on readily obtained clinical data is a more univer-
sal means to identify dogs with systemic inﬂamma-
tion.14
Several studies from individual centers in the United
Kingdom have been published recently, but each
described relatively few cases and studied distinct
aspects of the disease. Even with the beneﬁt of these
data, it is diﬃcult to summarize the demographics, ther-
apies and outcomes of the overall UK canine IMHA
population presenting to referral centers.15–17
In this study we aimed to address these knowledge
gaps by surveying case presentations, management
strategies and outcomes of dogs with IMHA present-
ing to multiple referral centers in the British Isles. In
addition, we aimed to test the association of illness-
severity markers ASA and SIRS status with outcome
and test the predictive ability of 2 previously published
IMHA-speciﬁc illness severity scores. We also aimed
to identify independent prognostic markers from our
own dataset using a multivariate analysis approach
and hypothesized that a multivariable scoring system
would predict survival better than individual variables
alone.
Materials and Methods
Sample Size
Based on previous publications we estimated case fatality at dis-
charge at 17%,16 and that 20% dogs would have previously identi-
ﬁed risk factors.6,18,19 We aimed to detect a 2-fold increase in case
fatality risk where such factors were present and therefore planned
to enroll 335 dogs.b
Case Recruitment
Collaborators were recruited by publication of a letter inviting
participation,20 and through direct contact with referral centers.
Data sharing was agreed in writing. Cases admitted from January
1, 2008 to December 31, 2009 were included retrospectively. Dogs
admitted between January 1, 2010 and December 31, 2012 were
enrolled prospectively. Dogs with primary, idiopathic IMHA
admitted to participating institutions within the study period were
eligible for inclusion. To maximize recruitment, the following pre-
viously published diagnostic criteria were used:13,16 anemia
(PCV<37%) AND at least one of the following: positive in-saline
agglutination test, OR a positive Coombs’ test, OR moderate-
marked spherocytosis identiﬁed by a board-certiﬁed clinical
pathologist. Dogs were excluded if evidence of a predisposing dis-
ease process was present.21 All dogs underwent diagnostic evalua-
tion according to their individual case histories as judged
appropriate by their attending primary clinicians. These diagnostic
evaluations (summarized in Table S1) were not standardized, but
aimed to identify potential underlying causes and typically
included CBC, serum biochemistry, thoracic, and abdominal imag-
ing, PCR testing for tick-borne infections by Babesia, Ehrlichia,
and Mycoplasma species and urine culture. Attending clinicians
determined case management.
Data Acquisition and Handling
Study data (Data S1) were collected using secure, web-based
software that enabled automated data export.c Historical, demo-
graphic, at-admission clinicopathologic, treatment, and outcome
data were recorded via a custom survey, accessible from January
1, 2010 to February 1, 2013, agreed in advance by all participating
centers (Data S2). The survey used dropdown menus, limited-re-
sponse questions and constrained textboxes to minimize errors.
Free-text boxes enabled addition of contextual comments to aid
interpretation. Raw data were regularly inspected and where neces-
sary, centers were contacted to correct erroneous or incomplete
entries. ASA status was assigned as follows: Grade 1, Normal;
Grade 2, Mild systemic disease; Grade 3, Severe systemic disease;
Grade 4, Life-threatening systemic disease; Grade 5, Moribund
patient, not expected to survive.22 Illness severity scores CHAOS,a
and Tokyo,9 were calculated as previously reported (Table 1). Sys-
temic inﬂammatory response syndrome (SIRS) was diagnosed
using published criteria: Temperature ≤100.0°F or ≥103.5°F; heart
rate >160 bpm, RR >40 bpm; leukocyte count ≤4,000/lL or
≥12,000/lL or ≥10% band neutrophils.23 Anisocytosis and poly-
chromasia were graded as mild, moderate, or severe as previously
described. Similarly, spherocytes were quantiﬁed in the monolayer
using a 1+ to 3+ scale, where 1+ equals 5–10 spherocytes per 1009
oil ﬁeld (2–4% of the RBCs); 2+ equals 11–50 (4–20%); and 3+
equals 51–150 spherocytes per ﬁeld (20–60%).21 Where discrepan-
cies between automated and manual platelet counts occurred,
manual counts were used for calculations. Saline agglutination
tests were performed using a drop of EDTA-anticoagulated blood
Table 1. Calculation of CHAOS and Tokyo illness
severity scores.
Canine hemolytic anemic objective score (CHAOS)
Age (year) If ≥7 score 2, otherwise score 0
Temperature (°F) If ≥102.0 score 1, otherwise score 0
Agglutination If present score 1, otherwise score 0
Albumin (g/dL) If <3.0 score 1, otherwise score 0
Bilirubin (mg/dL) If ≥5.0 score 2, otherwise score 0
Total Maximum score 7
Tokyo score
Sex Male score 1, Female score 0
Season Apr-Sept score 1, Oct-Mar score 0
Packed cell volume (%) If <20 score 1, otherwise score 0
Platelet count (9 103/lL) If <200 score 1, otherwise score 0
Total protein (g/dL) If <6.0 score 1, otherwise score 0
Total Maximum score 5
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mixed with a drop of saline on a microscope slide and examined
against a white background over a period of 1–2 minutes for gross
agglutination, followed by microscopic evaluation for diﬀerentia-
tion from rouleaux.
Data Analysis
Exported data were collated and analyzed using proprietary
software.d,e,f Data were assessed for normality prior to test selec-
tion. Although some variables were parametric, most were not,
thus variables are reported as median (interquartile range). To val-
idate use of the whole dataset for outcome analyses, retrospective,
and prospective data were compared using nonparametric tests.
To correct for multiple (m) comparisons while minimizing the
risk of dismissing signiﬁcant diﬀerences, the P-value was adjusted:
Padjusted = [0.05 x (m+1)] / (2m).
24 CHAOS, Tokyo, case, treatment,
and center variables were tested for association with death during
hospitalization and death by 30 days by univariate logistic regres-
sion. The eﬀect of center was assessed using multiple dichotomous
variables with a reference group.
Multivariable logistic regression using case variables was then
undertaken to generate prognostic models. Center and treatment
were excluded from the prognostic models because they were not
generalizable to other populations, and were potentially subject to
bias from ﬁnancial constraint and clinician preference respectively.
Previously, reported illness-severity scores (CHAOS and Tokyo)
were not included in the multivariable analyses. Candidate predic-
tor variables were chosen as follows: associated with outcome in
the univariate regression at P < .1; no evidence of collinearity
(correlation coeﬃcient <0.9); an event:variable ratio >5.25 For a
complete case analysis to be performed in the prognostic models,
only variables with <5% missing data were included.26 Alanine
aminotransferase (ALT), bilirubin, urea, and creatinine values
were indexed against (divided by) each center’s upper reference
interval to account for variations in reference ranges. All variables
were simultaneously entered into the model to maximize the pre-
dictive ability of prognostic models. Model accuracy was deter-
mined using 2 9 2 classiﬁcation tables. Model discrimination was
determined by calculating area under the receiver-operating char-
acteristic curve (AUROC). Model calibration was assessed by
Hosmer–Lemeshow goodness-of-ﬁt (model rejected if P < .05) and
visual inspection of the contingency table. Model utility was
assessed using Nagelkerke’s R2.
Results
Retrospective and Prospective Case Comparisons
Although our aim was to enroll 335 cases, the rate of
case recruitment was slower than anticipated. To mini-
mize time-dependent changes in case management, the
registry was closed early, limiting the study period to
5 years. Data from 276 cases (215 prospective, 61 retro-
spective) were collected. Only 3 variables diﬀered signiﬁ-
cantly between retrospective and prospective
populations (Table 2), which were therefore considered
suﬃciently comparable for subsequent combined analy-
ses.
Study Population Characteristics
All centers contributed cases, median 18 (29) per cen-
ter. There were 246 (89.1%) purebred dogs and 30
(10.9%) cross-breeds. Two breeds were particularly
prevalent: springer spaniels (n = 46, 16.7%) and cocker
spaniels (n = 46, 16.7%). Spayed females represented
47.4% (n = 131), entire females 13.8% (n = 38), cas-
trated males 27.2% (n = 75) and entire males 11.6%
(n = 32). Fourteen dogs (5.1%) had a foreign-travel his-
tory. Thirteen dogs (4.7%) were vaccinated within
30 days of presentation. Many cases (n = 121, 43.8%)
received medication in the month before presentation,
typically for clinical signs attributable to IMHA: antibi-
otics (n = 63, 22.8%), glucocorticoids (n = 46, 16.7%),
nonsteroidal anti-inﬂammatory drugs (n = 31, 11.2%),
and immunosuppressives (n = 13, 4.7%). Therapies for
chronic disorders including epilepsy, diabetes mellitus,
or hypothyroidism were administered to 31 dogs
(11.2%).
Clinicopathologic Data
Two hundred twenty dogs were in-saline agglutina-
tion positive (79.7%), 85/113 dogs (75.2%) with a
Coombs test result were positive, 183/254 (72.0%) dogs
had moderate-marked spherocytosis. Blood typing for
DEA 1 was attempted in 212 dogs (76.8%) and estab-
lished in 180 (65.2%): 95 (34.4%) were positive and 85
(30.8%) negative. The median ASA classiﬁcation was 3
(2–3), the median CHAOS was 3 (2–4) and the median
Tokyo score was 3 (2–3); 58.3% fulﬁlled 2/4 SIRS crite-
ria (n = 161), 19.9% fulﬁlled 3/4 SIRS criteria (n = 55).
Treatment
Most dogs (n = 244, 88.4%) received primary
immunosuppressives, 101 dogs (36.6%) received 2 ﬁrst-
line drugs and 9 (3.3%) received 3 (Table 3). Second-
line immunosuppressives were used in 156 dogs
(56.5%), 46 dogs (16.6%) received 2 additional drugs,
and 7 (2.5%) received 3. Second-line drugs were insti-
tuted on median day 3 (2–5) after admission.
Antithrombotics were administered to 210 dogs (76.0%)
including: aspirin (n = 182, 65.9%), low molecular-
weight heparin (n = 31, 11.1%), clopidogrel (n = 23,
8.3%) and unfractionated heparin (n = 10, 3.6%). Mul-
tiple antithrombotics were administered to 32 dogs
(11.6%). Packed red blood cells were administered to
205 dogs (74.3%) (125 received 1 unit, 53 received 2
and 26 received ≥3). Fresh whole blood was adminis-
tered to 21 dogs (7.6%) (17 received 1 unit and 4
received 2). Hemoglobin-based oxygen carrying solution
was administered to 32 dogs (11.6%) (18 received 1
unit, 10 received 2, and 4 received 3). Only 5 dogs
received fresh frozen plasma. More than 1 product type
was administered to 35 dogs (12.7%).
Survival
Two hundred and ﬁve (74.3%) dogs were discharged
from the hospital, equivalent to 25.7% mortality at dis-
charge. Of the 71 nonsurvivors, 56 (20.3%) were eutha-
nized and 15 (5.4%) died. Sixteen dogs (5.8%) were
discharged but subsequently were euthanized or died and
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2 dogs were lost to follow-up, such that 186 (67.4%) dogs
were alive at 30 days after admission, equivalent to 30-
day mortality of 32.6%. Twelve dogs underwent
necropsy and no underlying diseases were identiﬁed.
Predictive Value of CHAOS and Tokyo
In univariate analyses CHAOS, when dichotomized
as <3 or ≥3, was associated with death in hospital and
death within 30 days of admission. Tokyo score, when
dichotomized as <3 or ≥3, was not associated with any
of the 3 outcome measures (Table 4). ROC curve data
for CHAOS, Tokyo, and the prognostic score from the
multivariable models are reported in Table 5. The
AUROC point estimate and 95% conﬁdence intervals
for CHAOS scores were higher than those for Tokyo
scores. The 95% conﬁdence intervals for Tokyo scores
all included 0.5, suggesting it was little better than
chance at predicting outcome in this population.
Outcome Modeling
In univariate analyses, 8 candidate variables were
associated with both survival at discharge and survival
at 30 days (Table 4). There was no association between
center and death at discharge or at 30 days. Two vari-
ables were excluded for having >5% missing cases. Cen-
ter and the CHAOS and Tokyo scores were deliberately
excluded from multivariable modeling. For survival pre-
diction multivariable analyses, 6 variables were entered
Table 2. Descriptive statistics of clinicopathologic data for the retrospective, prospective and combined populations.
Variables signiﬁcantly diﬀerent between the prospective and retrospective populations (P < .05 after adjustment for
multiple comparisons) are indicated in bold typeface.
Variable
Retrospective Prospective Comparison Combined
Median (IQR) n Median (IQR) n P-value Median (IQR) n
Age 7 (5) 61 6 (4) 214 .25 6 (4.1) 275
ASA 3 (1) 51 3 (1) 215 .73 3 (1) 266
Heart rate 128 (34) 61 130 (39) 208 .43 130 (33) 269
Resp. rate 36 (24) 55 36 (16) 182 .06 36 (19) 237
Temperature 101.3 (1.5) 60 101.7 (1.6) 205 .07 101.7 (1.6) 265
Albumin 2.8 (0.7) 59 2.9 (0.6) 209 .86 2.9 (0.6) 268
Globulin 3.4 (1.2) 59 3.3 (1.0) 209 .89 3.3 (1.1) 268
ALT 65 (195) 59 44 (85) 209 .03 45 (98) 268
ALP 198 (274) 59 184 (229) 210 .08 189 (246) 269
Bilirubin 27.4 (81.6) 58 16.0 (53.5) 207 .09 17.1 (59) 265
Urea 8.1 (6.3) 59 7.5 (5.1) 210 .63 7.6 (5.3) 269
Creatinine 65 (24) 59 66.5 (28) 206 .44 66 (27) 265
PCV 14.5 (8.0) 61 14.0 (7.0) 215 .35 14.0 (7.2) 276
Leukocytes 26.5 (20.9) 61 21.6 (21) 213 .17 22.5 (21.4) 274
Neutrophils 19.3 (17.1) 61 16.0 (17.2) 214 .15 16.9 (17.2) 275
Monocytes 2.4 (3.7) 61 1.8 (3.0) 214 .08 2.0 (3.0) 275
Platelet count 200 (72) 57 186 (173) 213 .86 187 (147) 270
Retics 160.0 (234) 43 129.5 (224) 137 .15 137 (226) 180
CHAOS 3 (2) 57 3 (2) 215 .05 3 (2) 272
Tokyo 3 (1) 57 3 (1) 215 .31 3 (1) 272
Polychromasia 2 (1) 57 2 (2) 199 .09 2 (1) 256
Anisocytosis 3 (1) 38 2 (1) 204 <.01 2 (1) 242
Spherocytosis 2 (2) 58 2 (2) 196 .57 2 (2) 254
Breed Breed variation P = .57
Sex Sex variation P > .99
Drug (1st) 1st immunosuppressive drug variation P = .96
Drug (2nd) 2nd immunosuppressive drug variation P = .94
Antithrombotics Antithrombotic drug variation P = .84
+/ n +/ n P-value +/ n
Agglutination 50/11 61 170/45 215 .72 220/56 276
Icterus 31/27 58 75/135 210 .02 106/162 268
Pigmenturia 15/16 31 57/103 160 .23 72/119 191
Travel 0/61 61 14/201 215 .05 14/262 276
Medication 19/42 61 98/115 213 .04 117/157 274
Vaccination 2/59 61 11/204 215 .74 13/263 276
Discharged 46/15 61 159/56 215 .87 205/71 276
Alive at 30d 43/17 60 143/71 214 .53 186/88 274
ASA, American Society of Anesthesiologists physical status classiﬁcation; ALT, alanine transaminase activity; ALP, alkaline phosphatase
activity; Retics, absolute reticulocyte count. P < .03 were considered signiﬁcant at the P < .05 level after adjustment for multiple comparisons.
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into the ﬁnal model: SIRS, ASA classiﬁcation, ALT,
bilirubin, urea, and creatinine. For prediction of out-
come at discharge, this model was accurate in 82% of
cases. In multivariate analysis, 3 variables were indepen-
dently predictive of death in hospital: ASA classiﬁca-
tion, bilirubin, and urea. Three variables were
independently predictive of death by day 30: ASA clas-
siﬁcation, bilirubin, and creatinine (Table 6).
Discussion
This multicenter study provides an overview of case
characteristics, management, and outcome for 276 dogs
with primary IMHA treated at referral centers in the
British Isles between 2008 and 2012. Despite intensive
management with immunosuppressives, blood products,
and antithrombotics, the 30-day mortality rate was
32.6%. This ﬁgure is comparable to previous stud-
ies,4,7,27,28 perhaps suggesting our ability to treat IMHA
has not improved in recent years.
Illness-severity scores might help identify dogs that
might beneﬁt from treatment intensiﬁcation. This study
evaluated the association of 2 IMHA speciﬁc illness-
severity scores with outcome in our population. Of
these, CHAOS ≥3 was associated with increased odds
of death and in particular, a high CHAOS was associ-
ated with a risk of death during hospitalization. Tokyo
score was not useful for outcome prediction in our
study. We also found that ASA classiﬁcation ≥3 was
also associated with death, suggesting the subjective
assessment of experienced clinicians can be a reasonable
gauge of illness severity in IMHA. As can be seen from
the AUROC values (Table 5), the ﬁnal multivariate
model allows outcome to be predicted more accurately
than previously reported scoring systems. This is not
unexpected, since a model generated from our data
should describe our population better than those derived
from other populations, and independent evaluation of
our model in an unrelated population should be under-
taken to ensure its validity. It is noteworthy however that
of the 2 previously developed scores, the AUROC point
estimate and 95% conﬁdence intervals for CHAOS were
good, while the 95% conﬁdence intervals for Tokyo
included 0.5, suggesting it was little better than chance at
predicting outcome in our population.
Table 3. Summary of immunosuppressive and
antithrombotic therapies administered to the study pop-
ulation.
First-line drug n
% total
pop.
Median
(min–max) dose
Mode
frequency
Dexamethasone 121 43.8 0.3 mg/kg (0.15–2) Q24 h
Prednisolone 121 43.7 1.3 mg/kg (0.5–2.2) Q12 h
Azathioprine 78 28.2 2 mg/kg (1.23–2.5) Q24 h
Cyclosporine 30 10.9 5 mg/kg (3–7) Q24 h
hIVIG 5 1.8 0.5 g/kg (0.3–0.6) Q24 h
MMF 4 1.4 15 mg/kg (13–15) Q12 h
Second-line drug n
% total
pop.
Median
(min–max) dose
Mode
frequency
Prednisolone 78 28.2 1 mg/kg (0.65–2) Q12 h
Azathioprine 39 14.1 2 mg/kg (1–4) Q24 h
Cyclosporine 29 10.5 3.3 mg/kg (2–7) Q12 h
MMF 10 3.6 10 mg/kg (5–20) Q12 h
hIVIG 6 2.2 0.5 g/kg (0.2–0.5) Q24 h
Cytarabine 3 1.1 50 mg/m2 (50–100) Q12 h
Dexamethasone 1 0.4 0.3 mg/kg Q24 h
Cyclophosphamide 1 0.4 5 mg/kg Q12 h
Antithrombotic n
% total
pop.
Median
(min–max) dose
Mode
frequency
Aspirin 182 65.9 0.5 mg/kg (0.25–5) Q24 h
Dalteparin 31 11.2 150 IU/kg (100–250) Q8 h
Clopidogrel 23 8.3 2 mg/kg (0.25–4.5) Q24 h
UFH 10 3.6 200 IU/kg (75–200) Q8 h
hIVIG, human immunoglobulin g; MMF, mycophenolate mofe-
til; UFH, unfractionated heparin.
Table 4. Results of univariate analyses for association with death at discharge and death within 30 days of admis-
sion. Variables signiﬁcantly associated with the outcome variable (P < .1) are indicated in bold typeface.
Variable
Dead at discharge Dead at 30-days
P value OR
95% CI of OR
P value OR
95% CI of OR
Lower Upper Lower Upper
CHAOS score ≥3 <.01 4.162 2.178 7.951 <.01 3.560 1.998 6.341
Tokyo score .99 1.004 0.577 1.749 .22 1.391 0.818 2.365
SIRS ≥3/4 criteria .03 2.040 1.091 3.816 .04 1.917 1.044 3.521
ASA ≥3 <.01 3.205 1.541 6.665 <.01 2.663 1.411 5.027
Respiratory rate .20 1.010 0.995 1.026 .35 1.007 0.992 1.023
Pigmenturia <.01 2.536 1.330 4.834 .01 2.184 1.186 4.024
Autoagglutination .97 0.985 0.465 2.089 .98 0.991 0.484 2.029
ALT (indexed) .05 1.040 1.001 1.081 .06 1.039 0.999 1.081
Bilirubin (indexed) <.01 1.013 1.005 1.020 <.01 1.011 1.004 1.018
Urea (indexed) <.01 3.135 1.955 5.029 <.01 2.587 1.666 4.018
Creatinine (indexed) .06 2.356 0.956 5.804 <.01 9.892 2.677 36.548
CHAOS, canine hemolytic anemia objective score; SIRS, systemic inﬂammatory response syndrome; Abbreviations, ASA, American
Society of Anesthesiologists physical status classiﬁcation; ALT, alanine transaminase activity; OR, odds ratio.
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We used logistic regression analysis to assess the
association of individual clinical and clinicopathologic
variables with outcome. Individual variables with signif-
icant associations with outcome were combined into
multivariable models and the accuracy of these models
evaluated using 2 9 2 classiﬁcation tables that identify
how many dogs were correctly classiﬁed as dead or
alive. The AUROC values were higher for the ﬁnal mul-
tivariable model than for any of the individual variables
alone (data not shown). The ﬁnal 6-variable model for
prediction of outcome at discharge was accurate in 82%
cases. Although this suggests the model was highly
accurate, it should be noted that assuming every dog
was discharged alive would have been correct in 74% of
cases. The R2 values suggest that the 6 variables
(SIRS, ASA classiﬁcation, ALT, bilirubin, urea, and
creatinine) included in our death in hospital model
represent only a minority of the factors determining
outcome. In linear regression, a model containing all
the variables needed to explain outcome has R2 = 1.
While R2 values in logistic regression are pseudo-R2,
their interpretation is similar. For example, our 6-vari-
able model predicting death during hospitalization had
R2 = 0.304. This indicates that most of the factors that
inﬂuence the likelihood of death during hospitalization
were not included in our model. These unquantiﬁed
variables might be unidentiﬁed or unmeasured case
factors, the eﬀects of treatment and complications
including thrombosis.
Table 5. Comparison of the abilities of the Study
model, CHAOS and Tokyo scores to predict death at
discharge and day 30. Receiver operating characteristic
curve results for the Study model, CHAOS and Tokyo
scores.
Death at discharge
Score AUROC SE
Asymptotic
signiﬁcance
Asymptotic 95% CI
Lower Upper
Study model 0.775 0.035 <0.001 0.706 0.844
CHAOS 0.688 0.036 <0.001 0.618 0.758
Tokyo 0.519 0.040 0.641 0.440 0.598
Death at day 30
Score AUROC SE
Asymptotic
signiﬁcance
Asymptotic 95% CI
Lower Upper
Study model 0.729 0.036 <0.001 0.657 0.800
CHAOS 0.688 0.034 <0.001 0.622 0.755
Tokyo 0.542 0.037 0.261 0.470 0.615
AUROC, area under the receiver operating characteristic curve;
SE, standard error; 95% CI, conﬁdence intervals for odds ratio.
Table 6. Summary of multivariable logistic regression models. Variables signiﬁcantly associated with the outcome
variable (P < .05) are indicated in bold typeface.
Summary of independent predictive variables for death at discharge
Variable Coeﬃcient (B) SE P value Odds ratio (OR)
95% CI for OR
Lower Upper
SIRS ≥3/4 criteria 0.233 0.410 .57 1.263 0.565 2.823
ASA ≥3 0.997 0.475 .04 2.709 1.068 6.870
ALT (indexed) 0.028 0.019 .15 1.028 0.990 1.067
Bilirubin (indexed) 0.010 0.004 <.01 1.010 1.003 1.017
Urea (indexed) 1.114 0.331 <.01 3.046 1.592 5.830
Creatinine (indexed) 0.639 0.588 .28 0.528 0.167 1.670
Constant 3.333 0.507
AUROC 0.775 (95% CI 0.706–0.844)
Hosmer–Lemeshow P value .31
Nagelkerke’s R2 0.304
Summary of independent predictive variables for death at 30-days
Variable Coeﬃcient (B) SE P value Odds ratio (OR)
95% CI for OR
Lower Upper
SIRS ≥3/4 criteria 0.201 0.384 .60 1.222 0.576 2.593
ASA ≥3 0.776 0.386 .04 2.173 1.020 4.629
ALT (indexed) 0.025 0.018 .17 1.026 0.989 1.064
Bilirubin (indexed) 0.009 0.003 .01 1.009 1.002 1.016
Urea (indexed) 0.440 0.274 .11 1.552 0.907 2.655
Creatinine (indexed) 2.197 0.902 .02 8.996 1.537 52.672
Constant 3.449 0.579
AUROC 0.729 (95% CI 0.657–0.800)
Hosmer–Lemeshow P value .89
Nagelkerke’s R2 0.261
SE, standard error; 95% CI, conﬁdence intervals for odds ratio; AUROC, area under the receiver operating characteristic probability
curve; OR, odds ratio.
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Seventy-two dogs died before discharge, while a fur-
ther 16 did not survive to 30 days. Three variables were
predictive of outcome at both times, suggesting some
consistency between the causes of death during hospital-
ization and at 30 days. There was 1 diﬀerence in the pre-
diction models between outcomes at discharge versus
30 days: urea was independently predictive of outcome
at discharge but not at 30 days, while creatinine was not
independently predictive of outcome at discharge but
was at 30 days. The cause of these diﬀerences is unclear.
The association between creatinine concentration and
outcome at 30 days might suggest that end-organ dys-
function associated with hypoxemia, nephrotoxicity from
drug administration, or hemoglobinemia aﬀects med-
ium-term outcome. Acute kidney injury is associated
with nonsurvival in critically-ill dogs,29 and even small
deteriorations in kidney function can aﬀect outcome.30
Our intention was to test our hypotheses by enrolling
335 dogs; however, we were only successful in recruiting
276 dogs within a 5-year period. Although this might
have reduced our ability to identify reliable prognostic
markers, post hoc power calculations suggested we were
powered to detect a 2.02-fold change in case fatality,
which was almost exactly our goal. This study com-
bined retrospective and prospectively collected data into
1 dataset, to maximize the data available for analysis,
while minimizing the time taken for data collection. We
compared demographics, clinicopathologic data, and
treatment data for these populations prior to combining
them. Three statistically signiﬁcant diﬀerences were
identiﬁed between these 2 populations (ALT activity,
icterus frequency, and anisocytosis severity), but the
clinical relevance of these diﬀerences is debatable. The
absence of a diﬀerence in outcomes between the retro-
spective and the prospective groups supports this asser-
tion. We cannot exclude the possibility that other
diﬀerences might have existed that would aﬀect the
validity of our approach, but all data from the 2 parts
of the study were collected from the same group of cen-
ters, which should improve the homogeneity of the
data. Overall, we feel that the 2 populations were not
clinically diﬀerent suﬃcient that this would aﬀect the
results of our evaluation of associations using data from
the combined population.
Our analyses attempted to account for diﬀerences in
the reference intervals between centers. After initial
screening, it was determined that some variables should
be indexed to the institution’s reference intervals. Since
this was not performed for all variables, it is possible
we might have overlooked some signiﬁcant associations
between nonindexed variables and outcome. However
all of the variables in the ﬁnal models were indexed,
which maximizes their generalizability. We also consid-
ered that center might have had an eﬀect on outcome
either through distinct case demographics or institu-
tional diﬀerences in case management or treatment
availability. To address this, we evaluated the associa-
tion of center with outcomes in univariate analyses. We
found no signiﬁcant eﬀect of center on outcome in these
analyses. Center was deliberately excluded from the
multivariable analyses to maximize generalizability, but
regardless center would not have been included in our
multivariable models on the basis of a lack of associa-
tion in the univariate analyses. This argues that if dis-
tinct treatment strategies employed by diﬀerent
institutions signiﬁcantly inﬂuenced outcome then an
eﬀect of center on outcome might have been found, but
was not. The eﬀects of treatment on outcome were not
evaluated by this study directly, but warrant investiga-
tion in prospective interventional trials.
Although tailored diagnostic evaluation was performed
in all of the cases to identify an underlying mechanism for
their IMHA, this was not exhaustive and thus we cannot
exclude the possibility that some of these dogs had an
unidentiﬁed primary cause. For instance, many dogs
underwent PCR screening for vector-borne pathogens,
but few underwent more complete screening as has been
recently recommended.31 The potential eﬀect of this is
diﬃcult to quantitate, since unidentiﬁed primary causes
of IMHA might be expected to worsen the prognosis by
perpetuating the generation of autoantibodies. Other lim-
itations inherent in this study are biases induced by ﬁnan-
cial limitations and euthanasia. Assessing dogs managed
only at referral centers might have reduced these eﬀects
by reducing the number of dogs euthanized for ﬁnancial
limitations. Most deaths in this study were due to eutha-
nasia, however, with the inherent potential for confound-
ing by euthanasia for reasons other than illness-severity
or lack of response to treatment that is diﬃcult to codify
or exclude.
Conclusion
This large multicenter cohort study provides insight
into the current management and outcome of dogs with
IMHA treated in the British Isles. Two previously pub-
lished illness-severity scores (CHAOS and Tokyo) were
prospectively evaluated for their ability to predict out-
come in a population separate from that used to gener-
ate the score. Of these two, only CHAOS was
predictive of outcome in our population. Using our
large dataset, we identiﬁed that markers of kidney func-
tion, bilirubin concentration, and ASA classiﬁcation are
independently associated with outcome in dogs with
IMHA; a multivariate model combining illness severity
scores and clinicopathologic data correctly predicted
outcome at discharge in 82% cases. The ability of the
factors identiﬁed here to predict outcome can now be
evaluated in other populations, ideally before use as a
means to stratify dogs for prospective interventional
trials.
Footnotes
a Whelan MF, Rozanski EA, O’Toole TE, et al. Use of the canine
hemolytic anemia objective score (CHAOS) to predict survival in
dogs with immune mediated hemolytic anemia. J Vet Intern Med
2006; 20:714–715 [Abstract]
b http://wwwn.cdc.gov/epiinfo/html/ei6_downloads.htm
c https://www.surveymonkey.com
d Excel 2010, Microsoft
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e SPSS 21, IBM
f Prism 5.0, GraphPad
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